Trials / Completed
CompletedNCT02385097
Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block
A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 211 (actual)
- Sponsor
- Sintetica SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.
Detailed description
This Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min (see definitions below), calculated from the time of readiness for surgery (complete sensory block). Successful block: anaesthesia adequate for the surgery (complete sensory block), without any supplementation in the first 45 min (even if surgery lasts for \> 45 min), calculated from the time of readiness for surgery (complete sensory block). Supplementation: i.v. premedication or general anaesthesia or pre- or intra-operative systemic analgesia or additional local anaesthetic infiltration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chloroprocaine HCl 2% | Single Administration (20mL) by Axillary Nerve Route |
| DRUG | Ropivacaine 0.75% | Single Administration (20mL) by Axillary Nerve Route |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2015-03-11
- Last updated
- 2021-07-15
- Results posted
- 2021-07-15
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02385097. Inclusion in this directory is not an endorsement.